3-(4-(5-(4-((4S,5R)-2-(4-(tert-butyl)-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-1-yl)-5-oxopent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

ID: ALA4561949

PubChem CID: 155558694

Max Phase: Preclinical

Molecular Formula: C50H50Cl2N6O6

Molecular Weight: 901.89

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CCOc1cc(C(C)(C)C)ccc1C1=N[C@@H](c2ccc(Cl)cc2)[C@@H](c2ccc(Cl)cc2)N1C(=O)N1CCN(C(=O)CCC#Cc2cccc3c2CN(C2CCC(=O)NC2=O)C3=O)CC1

Standard InChI: InChI=1S/C50H50Cl2N6O6/c1-5-64-41-29-34(50(2,3)4)17-22-38(41)46-54-44(32-13-18-35(51)19-14-32)45(33-15-20-36(52)21-16-33)58(46)49(63)56-27-25-55(26-28-56)43(60)12-7-6-9-31-10-8-11-37-39(31)30-57(48(37)62)40-23-24-42(59)53-47(40)61/h8,10-11,13-22,29,40,44-45H,5,7,12,23-28,30H2,1-4H3,(H,53,59,61)/t40?,44-,45+/m0/s1

Standard InChI Key: SSAVNUNRQAALLH-JYJKVREKSA-N

Molfile:

 
     RDKit          2D

 64 71  0  0  0  0  0  0  0  0999 V2000
    4.3343  -23.5392    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5542  -23.7910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5538  -24.6155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3345  -24.8722    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.8189  -24.2029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8863  -23.3084    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9749  -22.4849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3063  -21.9965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5490  -22.3344    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4642  -23.1614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1337  -23.6421    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8874  -25.1040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1309  -24.7680    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4615  -25.2513    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5476  -26.0748    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3086  -26.4126    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9748  -25.9232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8789  -21.8466    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.8785  -26.5638    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    5.6420  -24.2003    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0585  -24.9179    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8848  -24.9165    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2957  -24.1983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8782  -23.4800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0532  -23.4849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5929  -22.7524    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4021  -22.5815    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.0383  -22.1364    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.9494  -23.2017    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7555  -23.0335    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0183  -22.2477    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.4645  -21.6298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6520  -21.7977    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1228  -24.1955    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5408  -24.9109    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5360  -23.4772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9487  -24.1943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6436  -25.6353    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.0600  -26.3517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6452  -27.0648    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8243  -22.0810    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0828  -21.2998    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3715  -22.6956    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.8887  -21.1330    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1473  -20.3517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4071  -19.5667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6657  -18.7853    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1826  -17.2255    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3730  -17.3956    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1182  -18.1759    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7302  -17.8410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4752  -18.6183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1355  -19.1011    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.7989  -18.6222    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.5482  -17.8435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.5788  -18.8762    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.7459  -19.6831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5238  -19.9404    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1401  -19.3944    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.9730  -18.5876    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.1897  -18.3268    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0338  -17.1790    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.0217  -17.5212    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.9210  -19.6539    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  3  1  0
  1  2  1  0
  3  4  1  0
  4  5  2  0
  5  1  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11  6  1  0
  2  6  1  1
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 12  1  0
  3 12  1  1
  9 18  1  0
 15 19  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 20  1  0
  5 20  1  0
  1 26  1  0
 26 27  1  0
 26 28  2  0
 27 29  1  0
 27 33  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 23 34  1  0
 34 35  1  0
 34 36  1  0
 34 37  1  0
 21 38  1  0
 38 39  1  0
 39 40  1  0
 31 41  1  0
 41 42  1  0
 41 43  2  0
 42 44  1  0
 44 45  1  0
 45 46  3  0
 46 47  1  0
 47 52  2  0
 51 48  2  0
 48 49  1  0
 49 50  2  0
 50 47  1  0
 51 52  1  0
 52 53  1  0
 53 54  1  0
 54 55  1  0
 55 51  1  0
 56 57  1  0
 56 61  1  0
 57 58  1  0
 58 59  1  0
 59 60  1  0
 60 61  1  0
 54 56  1  0
 55 62  2  0
 61 63  2  0
 59 64  2  0
M  END

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Unknown	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 901.89	Molecular Weight (Monoisotopic): 900.3169	AlogP: 8.09	#Rotatable Bonds: 8
Polar Surface Area: 131.93	Molecular Species: NEUTRAL	HBA: 7	HBD: 1
#RO5 Violations: 2	HBA (Lipinski): 12	HBD (Lipinski): 1	#RO5 Violations (Lipinski): 3
CX Acidic pKa: 11.61	CX Basic pKa: 3.84	CX LogP: 7.71	CX LogD: 7.71
Aromatic Rings: 4	Heavy Atoms: 64	QED Weighted: 0.14	Np Likeness Score: -0.22

References

1. Wang B, Wu S, Liu J, Yang K, Xie H, Tang W.. (2019) Development of selective small molecule MDM2 degraders based on nutlin., 176 [PMID:31128449] [10.1016/j.ejmech.2019.05.046]
2. Raboisson, Pierre P and 12 more authors. 2005-04-01 Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists. [PMID:15780621]
3. Schneekloth, Ashley R AR, Pucheault, Mathieu M, Tae, Hyun Seop HS and Crews, Craig M CM. 2008-11-15 Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. [PMID:18752944]
4. Hayashi, Ryo R and 5 more authors. 2009-12-01 N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53. [PMID:19880322]
5. Madden, Michael M and 5 more authors. 2011-03-01 Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition. [PMID:21277201]
6. Ghosh, Pradip P, Zhang, Jiawei J, Shi, Zheng-Zheng ZZ and Li, King K. 2013-04-15 Synthesis and evaluation of an imidazole derivative-fluorescein conjugate. [PMID:23477941]
7. Zhao, Yujun Y and 12 more authors. 2013-07-11 A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. [PMID:23786219]
8. Blackburn, Tim J and 14 more authors. 2013-09-21 Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and intermediates. Details for the biological evaluation. Further details for the modeling. Table of combustion analysis data. See DOI: 10.1039/c3md00161jClick here for additional data file. [PMID:24078862]
9. Li, Jin J and 14 more authors. 2014-06-15 Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy. [PMID:24813735]
10. Zheng, Guang-hui GH and 7 more authors. 2014-06-23 Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction. [PMID:24852275]
11. Rew, Yosup Y and 34 more authors. 2014-12-26 Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction. [PMID:25384157]
12. Zhao, Yujun Y, Aguilar, Angelo A, Bernard, Denzil D and Wang, Shaomeng S. 2015-02-12 Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. [PMID:25396320]
13. Aguilar, Angelo and 7 more authors. 2014-12-26 Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles. [PMID:25496041]
14. Neochoritis, Constantinos G and 8 more authors. 2015-12-15 2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists. [PMID:26584879]
15. Daniele, Simona S and 12 more authors. 2016-05-26 Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas. [PMID:27050782]
16. Aguilar, Angelo and 17 more authors. 2017-04-13 Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. [PMID:28339198]
17. Giustiniano, Mariateresa M and 18 more authors. 2017-10-12 Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structure-Activity Relationship Studies and Pharmacological Activity. [PMID:28921985]
18. Merlino, Francesco F and 20 more authors. 2018-06-14 Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme. [PMID:29775303]
19. Niazi, Sarfaraj S, Purohit, Madhusudan M and Niazi, Javed H JH. 2018-10-05 Role of p53 circuitry in tumorigenesis: A brief review. [PMID:30199707]
20. Wang, Bo B and 5 more authors. 2019-08-15 Development of selective small molecule MDM2 degraders based on nutlin. [PMID:31128449]
21. Sang, Peng and 10 more authors. 2020-02-13 α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions. [PMID:31971801]

3-(4-(5-(4-((4S,5R)-2-(4-(tert-butyl)-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-1-yl)-5-oxopent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source